Anti-malarial drug gets priority review designation

FORT DETRICK, Md. — The U.S. Food and Drug Administration recently granted priority review designation for Tafenoquine, a drug intended to prevent malaria in adults.

The announcement was made by the U.S. Army Medical Materiel Development Activity.

“Obtaining FDA priority review designation is another major step in accelerating this critically needed product through the regulatory review process towards licensure and fielding,” said Dr. Lawrence Lightner, USAMMDA project manager for the Pharmaceutical Systems Project Management Office.

The U.S. FDA may grant priority review designation for drugs intended for the prevention of serious conditions, such as malaria, that provide safety or efficacy improvements over currently available drugs.

USAMMDA develops and delivers medical capabilities to protect, treat and sustain the health of people in the military.